Join us in Philadelphia from Sept. 25-27th for our "Together We Will" Weekend: - Register today!

The Desmoid Tumor Research Foundation

March 2021

Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors

Author Information

Auloge P(1), Garnon J(1), Robinson JM(1), Thenint MA(2), Koch G(1), Caudrelier J(1), Weiss J(1), Cazzato RL(1), Kurtz JE(3), Gangi A(1).

(1)Service d'Imagerie Interventionnelle, Hopitaux Universitaires de Strasbourg, Strasbourg, France. (2)Service de Radiologie, Centre Francois Baclesse, Caen, France.(3)Service d'Oncologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France.

Publication

Int J Clin Oncol

Summary

This retrospective study reviewed 30 consecutive patients with symptomatic desmoid tumors evolving after "wait and watch" periods, and despite medical treatment, treated by percutaneous cryoablation (CA) between 2007 and 2019. Progression free survival (PFS), objective response rate, pain reduction (decreased of visual analogic scale pain (VAS)[Formula: see text] 3 or disappearance of pain), total volume lesion (TVL) and complications were documented. Kaplan Meier method was used to outline PFS. Paired sample t test was used to compare volume of tumors before treatment and at 1 and 3 year. With a median follow-up of 18.5 months (range 6-93 months, interquartile range (IQR): 12-55), the PFS was 85.1% at 1 year and 77.3% at 3 years. Objective response was obtained for 80% of patients with a complete response for 43% patients. Pain reduction was obtained for 96.7% (95% confidence interval (95% CI): 90.3, 100) of patients. Median volume of desmoid tumor before treatment was 124.1cm3 (range 2-1727cm3, IQR: 54-338cm3). Median change of TLV after ablation was 66.6% (95% CI: 37.2, 72.3; p = 0.002) at 1 year and 76.4% (95% CI: 59.1, 89.8; p = 0.002) at 3 year. Adverse events rate was 36.6%, the most common was edema and temporary increase of pain in the days following CA. Four patients experienced a major complication (13.3%): 2 skin necrosis, 1 infection and 1 brachial plexopathy. CA is an effective treatment for advanced and refractory extra-abdominal desmoid tumor, that induces durable responses.

View Abstract